Potential Dilution from the Exercise of Stock Acquisition Rights
First written in FY2016. 10 of 29 entries say "Worsened", first in FY2021-Q2. Latest entry: 2026-09-10.
Atrae moved to the "Worse" side of this theme in 2021, the same year as the typical company in this theme.
The whole theme swung hardest in 2017: 28 of 54 companies on the "Worse" side.
5 other companies' latest entry also says "Other".
- 2026-09-10Otherwww.nikkei.com
「また、同時に特別利益として新株予約権戻入益を計上することを明らかにした。」
新株予約権戻入益を特別利益として計上することを適時開示したが、記事では戻入れの対象数や希薄化への影響を示していない。 - 2026-09-10MitigatedRevision of earnings forecasts
「The Company has received requests from its officers, employees and others holding the subject stock acquisition rights to waive their rights to the stock acquisition rights held as of 30 September 2026. As a result, those stock acquisition rights are expected to lapse as of 30 September 2026, with the aim of dispelling concerns about future share dilution and increasing corporate value through appropriate share-price formation.」
Some of the Series 8 and Series 9 stock acquisition rights are expected to lapse on 30 September 2026, indicating a reduction in existing dilution exposure. However, stock acquisition rights outside the subject group will remain. - FY2025WorsenedAnnual report
「As of the end of the month preceding the date of filing this document (the end of November 2025), the number of potential shares represented by stock acquisition rights was 2,047,900, equivalent to approximately 9.0% of the total 22,827,141 issued shares.」
The number of potential shares represented by stock acquisition rights increased from 1,466,700, or approximately 6.1%, at the end of November 2024 to 2,047,900, or approximately 9.0%, expanding dilution exposure. - FY2025-H1WorsenedAnnual report
「The stock acquisition rights issued during the current interim accounting period were as follows. Common shares: 600,000. Exercise period for stock acquisition rights: 1 February 2027 to 12 January 2035.」
The Twelfth Series of Stock Acquisition Rights was newly issued, representing 600,000 common shares, adding exposure to dilution from potential shares. - FY2024WorsenedAnnual report
「As of the end of the month preceding the date of filing this document (the end of November 2024), the number of potential shares represented by stock acquisition rights was 1,466,700, equivalent to approximately 6.1% of the total 24,047,141 issued shares.」
The potential share ratio increased from approximately 3.0% at the end of November 2023 to approximately 6.1%, expanding dilution exposure from the exercise of stock acquisition rights. - FY2024-Q1WorsenedAnnual report
「At a Board of Directors meeting held on 12 January 2024, we resolved, pursuant to Articles 236, 238 and 240 of the Companies Act, to allot stock acquisition rights as stock options and options over our own shares to our employees and to the directors and employees of our subsidiaries, and issued them on 1 February 2024.」
The Eleventh Series of Stock Acquisition Rights was issued to 89 employees of the company, 2 subsidiary directors, and 14 subsidiary employees, adding exposure to dilution from new potential shares equivalent to 669,500 common shares. - FY2023WorsenedAnnual report
「As of the end of the month preceding the date of filing this document (the end of November 2023), the number of potential shares represented by stock acquisition rights was 812,100, equivalent to approximately 3.0% of the total 27,021,200 issued shares.」
The number of potential shares increased from 514,600, or approximately 1.9%, at the end of November 2022 to 812,100, or approximately 3.0%, expanding dilution exposure. - FY2023-Q2RestatedAnnual report
「During the six months ended 31 August 2023, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous consolidated fiscal year.」
States that there have been no material changes to previously disclosed risks, including the dilution of equity value through the exercise of stock acquisition rights. - FY2023-Q1WorsenedAnnual report
「Based on a resolution of the Board of Directors dated 13 January 2023, we resolved to allot stock acquisition rights as stock options and options over our own shares to our employees and to the directors and employees of our subsidiaries, and issued them on 1 February 2023.」
The Tenth Series of Stock Acquisition Rights was issued to 89 employees of the company, 2 subsidiary directors, and 14 subsidiary employees, adding exposure to dilution from new potential shares equivalent to 300,000 common shares. - FY2022WorsenedAnnual report
「As of the end of the month preceding the date of filing this document (the end of November 2022), the number of potential shares represented by stock acquisition rights was 514,600, equivalent to approximately 1.9% of the total 26,961,200 issued shares.」
The number of potential shares increased from 391,400, or approximately 1.5%, in the fiscal year ended September 2021 to 514,600, or approximately 1.9%, updating the dilution exposure. - FY2022-Q3MaterialisedAnnual report
「1 April 2022–30 June 2022 (Note) 72,000 26,961,200 360 1,231,463 360 1,217,463 (Note) This was an increase resulting from the exercise of stock acquisition rights.」
Discloses the fact that 72,000 shares increased during the third quarter accounting period as a result of the exercise of stock acquisition rights. - FY2022-Q1WorsenedAnnual report
「Based on a resolution of the Board of Directors dated 14 January 2022, we resolved to allot stock acquisition rights as stock options and options over our own shares to our employees and to the directors and employees of our subsidiaries, and issued them on 1 February 2022.」
New stock acquisition rights were issued to employees and subsidiary officers and employees, adding exposure to dilution from potential shares. - FY2021WorsenedAnnual report
「As of the date of filing this document, the number of potential shares represented by stock acquisition rights was 391,400, equivalent to approximately 1.5% of the total 26,779,200 issued shares.」
The number of potential shares increased to 391,400, including existing shares, from the previously disclosed 319,400 shares under the Eighth Series of Stock Acquisition Rights, presenting dilution exposure on a full-year basis. - FY2021-Q2WorsenedAnnual report
「The stock acquisition rights issued during the current second quarter accounting period were as follows. Common shares: 160,000 [320,000]. Exercise period for stock acquisition rights: 2 February 2023 to 1 February 2030.」
The Eighth Series of Stock Acquisition Rights was issued to 2 directors and 62 employees, with an underlying share count of 320,000 after adjustment for the stock split. This added exposure to dilution from new potential shares, with an exercise period from February 2023 to February 2030. - FY2020MitigatedAnnual report
「As of the date of filing this document, the number of potential shares represented by stock acquisition rights was 63,000, equivalent to approximately 0.5% of the total 13,362,600 issued shares.」
As shares have been issued through the exercise of stock acquisition rights, the potential share ratio has declined from 1.0% in the previous fiscal year to approximately 0.5%. - FY2020-Q3MaterialisedAnnual report
「7 May 2020 (Note) 18,000 13,308,600 171 1,122,905 171 1,108,905 (Note) This was an increase resulting from the exercise of stock acquisition rights.」
Discloses the fact that 18,000 shares increased as a result of the exercise of stock acquisition rights on 7 May 2020, bringing the total number of issued shares to 13,308,600. - FY2020-Q2RestatedAnnual report
「During the cumulative second-quarter period, there were no new business risks and no material changes in the business risks described in the annual securities report for the preceding fiscal year.」
States that there have been no material changes to previously disclosed risks, including the dilution of equity value through the exercise of stock acquisition rights. - FY2020-Q1RestatedAnnual report
「During the six months ended [current first quarter], there was no emergence of new business or other risks, nor any material change in the business or other risks described in the annual securities report for the previous fiscal year.」
States that there have been no material changes to previously disclosed risks, including the dilution of equity value through the exercise of stock acquisition rights. - FY2019MitigatedAnnual report
「As of the date of filing this document, the number of potential shares represented by stock acquisition rights was 135,000, equivalent to 1.0% of the total 13,277,600 issued shares.」
Following the increase in shares from the exercise of stock acquisition rights, the potential share ratio declined from 2.8% in the fiscal year ended September 2018 to 1.0%. - FY2019-Q3RestatedAnnual report
「During the cumulative third-quarter period, there were no new business risks and no material changes in the business risks described in the annual securities report for the preceding fiscal year.」
States that there have been no material changes to previously disclosed risks, including the dilution of equity value through the exercise of stock acquisition rights. - FY2019-Q2MaterialisedAnnual report
「1 January 2019–31 March 2019 (Note 2) 234,000 13,277,600 2,223 1,098,294 2,223 1,084,294 (Note) 2. This was an increase resulting from the exercise of stock acquisition rights.」
Discloses the fact that 234,000 shares increased during the cumulative second quarter as a result of the exercise of stock acquisition rights. - FY2019-Q1RestatedAnnual report
「During the six months ended [current first quarter], there was no emergence of new business or other risks, nor any material change in the business or other risks described in the annual securities report for the previous fiscal year.」
States that there have been no material changes to previously disclosed risks, including the dilution of equity value through the exercise of stock acquisition rights. - FY2018MitigatedAnnual report
「As of the date of filing this document, the number of potential shares represented by stock acquisition rights was 369,000, equivalent to 2.8% of the total 13,025,300 issued shares.」
The potential share ratio declined from 9.0% in the previous fiscal year to 2.8%, and the company discloses the remaining potential shares after the exercise of stock acquisition rights. - FY2018-Q3RestatedAnnual report
「During the cumulative third-quarter period, there were no new business risks and no material changes in the business risks described in the annual securities report for the preceding fiscal year.」
States that there have been no material changes to previously disclosed risks, including the dilution of equity value through the exercise of stock acquisition rights. - FY2018-Q2MaterialisedAnnual report
「Increase or decrease in the total number of issued shares: 231,000 shares. This was an increase resulting from the exercise of stock acquisition rights. (2) Status of stock acquisition rights, etc.: Not applicable.」
States that 231,000 shares increased during the cumulative second quarter as a result of the exercise of stock acquisition rights, while no stock acquisition rights or similar instruments were outstanding at the end of the quarter. - FY2017MitigatedAnnual report
「As of the date of filing this document, the number of potential shares represented by stock acquisition rights was 354,000, equivalent to 9.0% of the total 3,934,100 issued shares.」
The potential share ratio declined from 10.2% disclosed for the previous fiscal year to 9.0%. At the same time, the company disclosed a 42,000 increase in issued shares resulting from the exercise of stock acquisition rights during the fiscal year. - FY2017-Q3MaterialisedAnnual report
「The total number of issued shares increased by 42,000 as a result of the exercise of stock acquisition rights as of the date of filing this document.」
Discloses the fact that the number of issued shares increased by 42,000 as a result of the exercise of stock acquisition rights, indicating that an event related to potential dilution from potential shares has actually occurred. - FY2017-Q2RestatedAnnual report
「During the cumulative second-quarter period, there were no new business risks and no material changes in the business risks described in the annual securities report for the preceding fiscal year.」
States that there have been no material changes to previously disclosed risks, including the dilution of equity value through the exercise of stock acquisition rights. - FY2016First statedAnnual report
「As of the date of filing this document, the number of potential shares represented by stock acquisition rights was 132,000, equivalent to 10.2% of the total 1,292,600 issued shares.」
Discloses the potential dilution of existing shareholders’ equity value and voting rights from the exercise of stock acquisition rights, together with the figure of 10.2%.